BCTXZ
MaterialsBriaCell Therapeutics Corp Warrant
Live · NASDAQ · May 9, Close
What's Moving BCTXZ Today?
No stock-specific AI insight has been generated for BCTXZ yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.09
Fundamentals
Trading
BCTXZ News
20 articles- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer StudyYahoo Finance·May 7, 2026
- BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a StudyYahoo Finance·May 6, 2026
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast CancerYahoo Finance·May 6, 2026
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026Yahoo Finance·Apr 27, 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer ModelsYahoo Finance·Apr 21, 2026
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR MeetingYahoo Finance·Apr 20, 2026
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 LicenseYahoo Finance·Mar 31, 2026
- BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR ConferenceYahoo Finance·Mar 18, 2026
- BriaCell to Present Four Poster Presentations at the 2026 AACR Annual MeetingYahoo Finance·Mar 10, 2026
- BriaCell Therapeutics Corp. Announces Results of Shareholder MeetingYahoo Finance·Mar 5, 2026
- BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 LicenseYahoo Finance·Feb 18, 2026
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast CancerYahoo Finance·Feb 17, 2026
- BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationYahoo Finance·Jan 28, 2026
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer PatientsYahoo Finance·Jan 27, 2026
- BriaCell Therapeutics Announces Closing of US$30 million Public OfferingYahoo Finance·Jan 15, 2026
- Top Midday DeclinersYahoo Finance·Jan 14, 2026
- BriaCell Therapeutics Announces Pricing of $30 million Public OfferingYahoo Finance·Jan 14, 2026
- Top Midday GainersYahoo Finance·Jan 13, 2026
- BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ PatientYahoo Finance·Jan 13, 2026
- “Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature MedicineYahoo Finance·Dec 18, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.09
Fundamentals
Trading
About BriaCell Therapeutics Corp Warrant
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company dedicated to pioneering immunotherapies for cancer, with a primary focus on breast cancer treatment. Its lead candidate, Bria-IMT, has demonstrated encouraging efficacy in early clinical trials, underscoring the company's commitment to addressing substantial unmet medical needs in oncology. Backed by a strong research and development infrastructure and an experienced leadership team, BriaCell is well-positioned to drive significant innovations in cancer therapeutics and enhance patient outcomes in a dynamic market.